Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

eculizumab 3fludarabine 2Cyclophosphamide 2ublituximab 1thymoglobulin 1ravulizumab 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1Sugars 1Rituximab 1Prednisone 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Melphalan 1LFB-R603 1Immunoglobulins, Intravenous 1Etoposide 1Cytarabine 1Carmustine 1Antilymphocyte Serum 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neuromyelitis Optica × Rituximab × Clear all
NCT00501748 2011-09-27

Safety and Tolerability of Rituximab in Neuromyelitis Optica

University of California, San Francisco

Phase 1 Completed
20 enrolled

Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡